Description:
Peficitinib is a potent JAK inhibitor with IC50 values of 3.9, 5.0, 0.71 and 4.8 nM for JAK1, JAK2, JAK3 and TYK2 enzyme activities, respectively. It inhibits the IL-2-induced proliferation of human T cells with IC50 value of 18 nM. Moreover, peficitinib is 14-fold more potent against JAK1/3 than JAK2/2 on the basis of EPO-induced proliferation of human leukemia cells. Peficitinib has been used for the treatment of psoriasis and rheumatoid arthritis.
- Molecular Weight:326.39
- Purity:>98%
Molecular Formula:
C18H22N4O2
Canonical SMILES:
C1C2CC3CC(C2)(CC1C3NC4=C5C=CNC5=NC=C4C(=O)N)O
InChI:
InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9?,10-,11+,14?,18?
InChIKey:
DREIJXJRTLTGJC-JQCLMNFQSA-N
Solubility:
Soluble to 65 mg/mL in DMSO.
Appearance:
Light Yellow Solid
Application:
Inhibited JAK1, JAK2, JAK3 and TYK2 enzyme activities with IC50 values of 3.9, 5.0, 0.71 and 4.8 nM, respectively; Inhibited the IL-2-induced proliferation of human T cells with an IC50 value of 18 nM
Synonyms:
ASP015K; ASP-015K; 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide Weitere Informationen finden Sie
hier